PMID- 35107598
OWN - NLM
STAT- MEDLINE
DCOM- 20220530
LR  - 20220530
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Linking)
VI  - 30
IP  - 7
DP  - 2022 Jul
TI  - An overview of the efficacy of phototherapy in oncodermatology.
PG  - 5591-5600
LID - 10.1007/s00520-022-06841-w [doi]
AB  - BACKGROUND: Cutaneous adverse events (AEs) following cancer immunotherapy, 
      targeted therapy, and chemotherapy have been well-documented in the literature. A 
      number of case reports have identified phototherapy, a form of light therapy that 
      mimics sunlight exposure, as a noninvasive treatment modality for these cutaneous 
      toxicities. By inducing local suppression of the immune system, phototherapy is a 
      skin-directed treatment with minimal effect on tumor response. Phototherapy may 
      therefore be a viable treatment option for cutaneous AEs from cancer therapies. 
      METHODS: We reviewed the literature for patients treated with phototherapy for 
      cutaneous AEs following cancer immunotherapy, targeted therapy, or chemotherapy. 
      We also included three previously unpublished cases from our own institution. 
      RESULTS: We identified 24 patients (80% male, mean age 67 years, range 
      49-75 years). Patients received the following phototherapy types: NB-UVB 
      (n = 17), PUVA (n = 6), or PDT (n = 1). A topical steroid was used in conjunction 
      with phototherapy in seven patients. At phototherapy onset, cancer treatment was 
      either continued, temporarily discontinued, or discontinued (n = 9, 6, 7, 
      respectively; in two cases, the cancer treatment course was unknown). Improvement 
      of cutaneous AEs was observed in 96% of patients. CONCLUSIONS: Phototherapy 
      resulted in full or partial improvement in all but one patient. A topical steroid 
      was used in nearly a third of patients, suggesting some oncodermatologists 
      co-administer topicals to further boost response. Continuation of cancer therapy 
      in the majority of patients highlights an additional advantage of phototherapy. 
      We believe phototherapy may be an effective adjunctive treatment to topical 
      steroids when treating these cutaneous toxicities.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Park, Candice
AU  - Park C
AD  - The Ohio State University College of Medicine, Columbus, OH, USA.
FAU - Korman, Abraham M
AU  - Korman AM
AD  - The Ohio State University Wexner Medical Center, Columbus, OH, USA.
FAU - Dulmage, Brittany L
AU  - Dulmage BL
AD  - The Ohio State University Wexner Medical Center, Columbus, OH, USA. 
      Brittany.Dulmage@osumc.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220202
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
SB  - IM
MH  - Administration, Cutaneous
MH  - Aged
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phototherapy/adverse effects/methods
MH  - Skin
MH  - Treatment Outcome
MH  - *Ultraviolet Therapy/adverse effects/methods
OTO - NOTNLM
OT  - Cutaneous adverse events
OT  - Immunotherapy
OT  - Oncodermatology
OT  - Phototherapy
EDAT- 2022/02/03 06:00
MHDA- 2022/05/31 06:00
CRDT- 2022/02/02 12:14
PHST- 2021/06/23 00:00 [received]
PHST- 2022/01/17 00:00 [accepted]
PHST- 2022/02/03 06:00 [pubmed]
PHST- 2022/05/31 06:00 [medline]
PHST- 2022/02/02 12:14 [entrez]
AID - 10.1007/s00520-022-06841-w [pii]
AID - 10.1007/s00520-022-06841-w [doi]
PST - ppublish
SO  - Support Care Cancer. 2022 Jul;30(7):5591-5600. doi: 10.1007/s00520-022-06841-w. 
      Epub 2022 Feb 2.